pubmed-article:11884288 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:11884288 | lifeskim:mentions | umls-concept:C0026809 | lld:lifeskim |
pubmed-article:11884288 | lifeskim:mentions | umls-concept:C0026473 | lld:lifeskim |
pubmed-article:11884288 | lifeskim:mentions | umls-concept:C0016390 | lld:lifeskim |
pubmed-article:11884288 | lifeskim:mentions | umls-concept:C0064847 | lld:lifeskim |
pubmed-article:11884288 | lifeskim:mentions | umls-concept:C1334350 | lld:lifeskim |
pubmed-article:11884288 | lifeskim:mentions | umls-concept:C0392756 | lld:lifeskim |
pubmed-article:11884288 | lifeskim:mentions | umls-concept:C0680242 | lld:lifeskim |
pubmed-article:11884288 | pubmed:issue | 3 | lld:pubmed |
pubmed-article:11884288 | pubmed:dateCreated | 2002-3-8 | lld:pubmed |
pubmed-article:11884288 | pubmed:abstractText | Leukotriene B4 (LTB4) is a potent chemotactic agent that activates monocytes through the LTB4 receptor (BLTR). We tested the hypothesis that LTB4 receptor blockade would slow atherosclerotic progression by inhibiting monocyte recruitment. Homozygous low-density receptor knockout (LDLr(-/-)) mice and apolipoprotein E deficient (apoE(-/-)) mice were treated with a specific LTB4 receptor antagonist, CP-105,696, for 35 days. In apoE(-/-)mice, treatment with the LTB4 antagonist did not affect plasma lipid concentrations but significantly reduced CD11b levels both in vascular lesions and whole blood. Compared with age-matched controls, lipid accumulation and monocyte infiltration were significantly reduced in treated apoE(-/-) mice at all time points tested. Lesion area reduction was also demonstrated in LDLr(-/-) mice maintained on a high-fat diet. LTB4 antagonism had no significant effect on lesion size in mice possessing the null alleles for another chemotactic agent, monocyte chemoattractant protein-1 (MCP-1(-/-)xapoE(-/-)), suggesting MCP-1 and LTB4 may either interact or exert their effects by a common mechanism. These results demonstrate that in a preclinical model of atherosclerosis LTB4 receptor blockade reduces lesion progression and further suggest a previously unrecognized role for LTB4 or other oxidized lipids recognized by the BLTR receptor in the pathogenesis of this disease. | lld:pubmed |
pubmed-article:11884288 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11884288 | pubmed:language | eng | lld:pubmed |
pubmed-article:11884288 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11884288 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:11884288 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11884288 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11884288 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11884288 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11884288 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11884288 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11884288 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11884288 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11884288 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11884288 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11884288 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11884288 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11884288 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11884288 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11884288 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:11884288 | pubmed:month | Mar | lld:pubmed |
pubmed-article:11884288 | pubmed:issn | 1524-4636 | lld:pubmed |
pubmed-article:11884288 | pubmed:author | pubmed-author:AielloRobert... | lld:pubmed |
pubmed-article:11884288 | pubmed:author | pubmed-author:BourassaPatri... | lld:pubmed |
pubmed-article:11884288 | pubmed:author | pubmed-author:LindseySaraly... | lld:pubmed |
pubmed-article:11884288 | pubmed:author | pubmed-author:WengWeifanW | lld:pubmed |
pubmed-article:11884288 | pubmed:author | pubmed-author:FreemanAnnA | lld:pubmed |
pubmed-article:11884288 | pubmed:author | pubmed-author:ShowellHenry... | lld:pubmed |
pubmed-article:11884288 | pubmed:issnType | Electronic | lld:pubmed |
pubmed-article:11884288 | pubmed:day | 1 | lld:pubmed |
pubmed-article:11884288 | pubmed:volume | 22 | lld:pubmed |
pubmed-article:11884288 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:11884288 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:11884288 | pubmed:pagination | 443-9 | lld:pubmed |
pubmed-article:11884288 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
pubmed-article:11884288 | pubmed:meshHeading | pubmed-meshheading:11884288... | lld:pubmed |
pubmed-article:11884288 | pubmed:meshHeading | pubmed-meshheading:11884288... | lld:pubmed |
pubmed-article:11884288 | pubmed:meshHeading | pubmed-meshheading:11884288... | lld:pubmed |
pubmed-article:11884288 | pubmed:meshHeading | pubmed-meshheading:11884288... | lld:pubmed |
pubmed-article:11884288 | pubmed:meshHeading | pubmed-meshheading:11884288... | lld:pubmed |
pubmed-article:11884288 | pubmed:meshHeading | pubmed-meshheading:11884288... | lld:pubmed |
pubmed-article:11884288 | pubmed:meshHeading | pubmed-meshheading:11884288... | lld:pubmed |
pubmed-article:11884288 | pubmed:meshHeading | pubmed-meshheading:11884288... | lld:pubmed |
pubmed-article:11884288 | pubmed:meshHeading | pubmed-meshheading:11884288... | lld:pubmed |
pubmed-article:11884288 | pubmed:meshHeading | pubmed-meshheading:11884288... | lld:pubmed |
pubmed-article:11884288 | pubmed:meshHeading | pubmed-meshheading:11884288... | lld:pubmed |
pubmed-article:11884288 | pubmed:meshHeading | pubmed-meshheading:11884288... | lld:pubmed |
pubmed-article:11884288 | pubmed:meshHeading | pubmed-meshheading:11884288... | lld:pubmed |
pubmed-article:11884288 | pubmed:meshHeading | pubmed-meshheading:11884288... | lld:pubmed |
pubmed-article:11884288 | pubmed:meshHeading | pubmed-meshheading:11884288... | lld:pubmed |
pubmed-article:11884288 | pubmed:meshHeading | pubmed-meshheading:11884288... | lld:pubmed |
pubmed-article:11884288 | pubmed:meshHeading | pubmed-meshheading:11884288... | lld:pubmed |
pubmed-article:11884288 | pubmed:meshHeading | pubmed-meshheading:11884288... | lld:pubmed |
pubmed-article:11884288 | pubmed:meshHeading | pubmed-meshheading:11884288... | lld:pubmed |
pubmed-article:11884288 | pubmed:meshHeading | pubmed-meshheading:11884288... | lld:pubmed |
pubmed-article:11884288 | pubmed:meshHeading | pubmed-meshheading:11884288... | lld:pubmed |
pubmed-article:11884288 | pubmed:year | 2002 | lld:pubmed |
pubmed-article:11884288 | pubmed:articleTitle | Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice. | lld:pubmed |
pubmed-article:11884288 | pubmed:affiliation | Department of Cardiovascular and Metabolic Disease, Pfizer Global Research and Development, Groton, Conn 06340, USA. robert_j_aiello@groton.pfizer.com. | lld:pubmed |
pubmed-article:11884288 | pubmed:publicationType | Journal Article | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11884288 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11884288 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11884288 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11884288 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11884288 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11884288 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11884288 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11884288 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11884288 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11884288 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11884288 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11884288 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11884288 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11884288 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11884288 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11884288 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11884288 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11884288 | lld:pubmed |